期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 127, 期 12, 页码 4415-4420出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI93486
关键词
-
资金
- National Institutes of Health [P01AI-076210, R21-AI124101, AI-106934, K08AI116979-01]
- Perkin Fund
- Jeffrey Modell Translational Research Award
- Chilean Ministry of Education by the CONICYT [PAI/INDU-STRIA 79090016]
Primary immunodeficiencies are often monogenic disorders characterized by vulnerability to specific infectious pathogens. Here, we performed whole-exome sequencing of a patient with disseminated Mycobacterium abscessus, Streptococcus viridians bacteremia, and cytomegalovirus (CMV) viremia and identified mutations in 2 genes that regulate distinct IFN pathways. The patient had a homozygous frameshift deletion in IFNGR2, which encodes the signal transducing chain of the IFN-gamma receptor, that resulted in minimal protein expression and abolished downstream signaling. The patient also harbored a homozygous deletion in IFNAR1 (IFNAR1(*557Gluext*46)), which encodes the IFN-alpha receptor signaling subunit. The IFNAR1(*557Gluext*46) resulted in replacement of the stop codon with 46 additional codons at the C-terminus. The level of IFNAR1(*557Gluext*46) mutant protein expressed in patient fibroblasts was comparable to levels of WT IFNAR1 in control fibroblasts. IFN-alpha-induced signaling was impaired in the patient fibroblasts, as evidenced by decreased STAT1/STAT2 phosphorylation, nuclear translocation of STAT1, and expression of IFN-alpha-stimulated genes critical for CMV immunity. Pretreatment with IFN-alpha failed to suppress CMV protein expression in patient fibroblasts, whereas expression of WT IFNAR1 restored IFN-alpha-mediated suppression of CMV. This study identifies a human IFNAR1 mutation and describes a digenic immunodeficiency specific to type I and type II IFNs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据